Job Information
Boehringer Ingelheim Executive Director, Early Asset TA Lead - Oncology in Ridgefield, Connecticut
Description
As an employee of Boehringer Ingelheim, you will actively contribute to the discovery, development, and delivery of our products to our patients and customers. Our global presence provides opportunity for all employees to collaborate internationally, offering visibility and opportunity to directly contribute to the companies' success. We realize that our strength and competitive advantage lie with our people. We support our employees in several ways to foster a healthy working environment, meaningful work, diversity and inclusion, mobility, networking, and work-life balance. Our competitive compensation and benefit programs reflect Boehringer Ingelheim's high regard for our employees.
The Executive Director, Early Asset TA Lead is a pivotal role responsible for alignment of the strategic direction of global early asset programs to optimize success for US patients and stakeholders. This role is responsible for leading the cross-functional US early assets TA team (Medicine and Value & Access) and Clinical Development role(s) within their assigned TA. The US Early Assets TA lead possesses broad expertise in the science of clinical development, and familiarity with the unique evidence generation needs of US regulatory, payer, and health systems customers. They also have extensive experience navigating the US legal and compliance landscape within a pharmaceutical environment. They leverage this expertise – together with their leadership and influencing skills – to co-create early asset strategies with global Early Asset teams to ensure the strategic direction of these programs optimize product approval, clinical adoption, product access and competitiveness in the US.
As the accountable point of contact for global early asset teams in the US, the US Early Assets TA Lead leverages exceptional advocacy, communication, and negotiation skills to co-create strategies with the global Early Asset teams, ensuring that US-specific considerations are prioritized and implemented in the strategic and tactical planning for early assets. The ED, Early Asset TA Lead will be required to engage with the most senior US and global TA Leadership to proactively raise and mitigate strategic issues, as well as advocate for US needs in development plans. The incumbent inspires the collective early assets team to consider the patient first and foremost and drives holistic, innovative solutions that serve the unique needs of patients.
Duties & Responsibilities
Inspires and challenges the cross-functional Early Assets TA team, together with integration and deliverable teams, to design innovative approaches that are fit-for-purpose for US patients and market needs.
Actively solicits team expertise and input in the early asset development programs and deliverables (e.g., early TPP, AEP, Integrated Evidence Plan, etc.)
Serves as challenge partner to integration and/or deliverable teams as appropriate to ensure alignment on strategy.
Manages critical interfaces across Value & Access and Medicine to ensure cohesive cross-functional planning and execution.
Responsible for smart risk taking and smart risk management, ensuring inclusion of legal and compliance representatives in decision-making as appropriate.
Manages Clinical Development roles within their assigned TA.
Early Assets Development Leadership:
Accountable for all aspects of US Early Assets TA strategy and planning.
Co-creates the early ambition and early clinical development strategy with global early asset team that accounts for US market considerations and requirements (e.g., early target product profile, asset evidence plan, etc.)
Drives accountability, together with the Early Assets TA team to ensure evidence generation needs are met for U.S. stakeholders.
Provides oversite and direction of early and strategic partnerships with external stakeholders.
Leveraging multi-functional knowledge, drives the cross-functional alignment of US strategy and proposals to address clinical, regulatory, access and commercial needs.
Owns the overall success of the early asset development in the US.
Works with leadership to ensure resources required to drive success of early assets are secured within appropriate functional budgets.
Communicates and represents aligned assets strategies and plans at all organizational levels.
Facilitates resolution of cross-functional project issues and escalates to management, as required.
Is an active member of the cross TA Early Assets community, ensuring close collaboration and alignment with the other Early Assets TA leads and teams.
Global Collaboration
Co-creates asset development strategy and planning with global early asset teams that accounts for US market specificities.
Primary contact for Global Leadership regarding early asset development strategy, planning and execution.
Collaborates with global and local teams to prepare for asset development scenarios and ensure the respective teams’ execution.
Planning:
Accountable for strategic business planning related to the early assets within the assigned TA (i.e., early ICP, etc.)
Leads discussions with Early Assets TA team and integration, deliverable teams as required, during the business planning cycles leading to long term forecast (LTF). Off-cycle, accountable for leading strategic discussions to escalate budget requests to respective functional leadership.
Leads decision escalation process as needed.
May aggregate budget for reporting purposes to Global and Local senior leadership.
Ensures budget and resourcing will effectively support early asset development for US.
Requirements
Bachelor's degree required, Masters or Doctoral degree preferred.
Minimum of ten (10) years’ experience in the pharmaceutical industry.
Experience in clinical research, medical affairs and/or drug development required.
Minimum of eight (8) years’ experience with Team and/or Project Leadership.
Excellent judgment – regarding the “how”, “what” and “when” of addressing Sr. Leaders and key stakeholders with sensitive issues.
Excellent understanding of clinical development, regulatory and commercial needs, processes, and related interfaces, including the US Medical, Regulatory and Market Access environment and requirements.
Excellent teamwork, negotiation, and collaboration abilities.
Excellent influencing and oral/written communication skills.
Excellent analytical thinking and critical thinking abilities, including the ability to solve complex problems and to proactively identify potential issues.
Demonstration of Accountability, Agility & Intrapreneurship (AAI) competencies and leadership of teams to deliver on AAI competencies.
Ability to travel overnight domestically and/or internationally, as needed.
Eligibility Requirements :
Must be legally authorized to work in the United States without restriction.
Must be willing to take a drug test and post-offer physical (if required).
Must be 18 years of age or older.
Compensation
This position offers a base salary typically between $184,000 and $325,000. The position may be eligible for a role specific variable or performance based bonus and or other compensation elements. For an overview of our benefits please click here. (https://www.boehringer-ingelheim.com/us/careers/benefits-rewards)
All qualified applicants will receive consideration for employment without regard to a person’s actual or perceived race, including natural hairstyles, hair texture and protective hairstyles; color; creed; religion; national origin; age; ancestry; citizenship status, marital status; gender, gender identity or expression; sexual orientation, mental, physical or intellectual disability, veteran status; pregnancy, childbirth or related medical condition; genetic information (including the refusal to submit to genetic testing) or any other class or characteristic protected by applicable law.
Boehringer Ingelheim
-
- Boehringer Ingelheim Jobs